| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Ubiquitin-specific protease 7 (USP7 / HAUSP). HBX-41108 is an inhibitor of USP7, which deubiquitinates and stabilizes p53, MDM2, and other substrates. By inhibiting USP7, it may modulate p53 activity and induce apoptosis in cancer cells.
|
|---|---|
| ln Vitro |
HBX-41108 inhibits USP7 activity. Specific IC50 values for USP7 inhibition are not detailed in the available literature. As a USP7 inhibitor, it would be expected to increase p53 levels and induce apoptosis in cancer cells.
|
| ln Vivo |
Specific in vivo activity data for HBX-41108 are not detailed in the available literature. As a USP7 inhibitor, it would be expected to have antitumor activity in vivo, but specific animal model studies are not described.
|
| Enzyme Assay |
In vitro enzyme inhibition assays for HBX-41108 involve measuring the deubiquitinating activity of USP7 in the presence of varying concentrations of the compound. The enzyme is incubated with a ubiquitinated substrate, and the removal of ubiquitin is quantified. The IC50 is determined from the dose-response curve.
|
| Cell Assay |
In vitro cell-based assays for HBX-41108 assess its effects on USP7 activity and p53 levels in cancer cells. Cells are treated with HBX-41108, and p53 levels, apoptosis, and cell viability are measured. The compound's effects on USP7-mediated deubiquitination can also be assessed.
|
| Animal Protocol |
Specific in vivo animal model protocols for HBX-41108 are not described in the available literature. To evaluate its in vivo efficacy, HBX-41108 could be administered to mouse xenograft models of cancer. Tumor growth inhibition and p53 activation would be measured.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for HBX-41108 are not reported in the available literature. As a small molecule inhibitor, its absorption, distribution, metabolism, and excretion properties would need to be characterized.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for HBX-41108 are not available. As a research compound, its safety profile has not been comprehensively characterized. Toxicity studies would be required to determine its safety margin.
|
| References |
|
| Additional Infomation |
HBX-41108 is a research tool for studying USP7 function and the role of deubiquitination in cancer. USP7 is a validated target for cancer therapy, and inhibitors like HBX-41108 are used to investigate the therapeutic potential of USP7 inhibition. It is not an approved therapeutic agent.
|
| Molecular Formula |
C13H3CLN4O
|
|---|---|
| Molecular Weight |
266.64212
|
| Exact Mass |
266
|
| Elemental Analysis |
C, 58.56; H, 1.13; Cl, 13.29; N, 21.01; O, 6.00
|
| CAS # |
924296-39-9
|
| PubChem CID |
16065773
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.66g/cm3
|
| Boiling Point |
604.9ºC at 760 mmHg
|
| Flash Point |
319.6ºC
|
| Index of Refraction |
1.725
|
| LogP |
2.084
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
19
|
| Complexity |
503
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N#CC1C(C#N)=NC2=C(C(C3C2=CC=C(Cl)C=3)=O)N=1
|
| InChi Key |
BIGPXXAUSQLTQR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H3ClN4O/c14-6-1-2-7-8(3-6)13(19)12-11(7)17-9(4-15)10(5-16)18-12/h1-3H
|
| Chemical Name |
7-Chloro-9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile
|
| Synonyms |
HBX-41108HBX41108HBX 41,108HBX 41108 HBX-41,108 HBX41,108.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~937.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (3.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 + to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7504 mL | 18.7519 mL | 37.5038 mL | |
| 5 mM | 0.7501 mL | 3.7504 mL | 7.5008 mL | |
| 10 mM | 0.3750 mL | 1.8752 mL | 3.7504 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA